Here are five notes:
1. EyePoint Pharmaceuticals’ Yutiq is a non-bioerodible intravitreal micro-insert that utilizes the company’s Durasert drug delivery technology. The drug delivery system is designed to release 0.18 mg fluocinolone acetonide consistently over three years.
2. Yutiq can be administered in the physician’s office through a sterile single-dose preloaded applicator.
3. The FDA approved YUTIQ based on clinical data from two Phase 3 clinical trials. After six and 12 months, Yutiq caused a statistically significant reduction in the rate of recurrent uveitis flares compared to sham. Cataract development and increased intraocular pressure were the most common adverse reactions reported.
4. EyePoint plans to launch the Yutiq in the first quarter of 2019.
5. In 2019, EyePoint also plans to launch Dexycu and seek FDA approval for a shorter-duration treatment for chronic non-infectious uveitis of the posterior segment.
More articles on supply chain:
3 most common supply chain challenges for ASCs
ASC supply chain tip of the day: Create a stronger enterprise structure
4 Ways a Clinical Assessment Drives Value for Your Surgery Center
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
